Bioequivalence Study And Pharmacokinetic Evaluation Of Two Quetiapine Formulations In Healthy Volunteers After A Single Dose Administration [estudo De Bioequivalência E Avaliação Farmacocinética De Duas Formulações De Quetiapina Em Voluntários Sadios Após Administração De Dose única]

dc.creatorAbib Jr. E.
dc.creatorDuarte L.F.
dc.creatorPereira R.
dc.creatorSavio D.
dc.creatorPengo S.
dc.creatorMorais D.C.
dc.creatorDe Lima L.G.
dc.date2011
dc.date2015-06-30T20:27:27Z
dc.date2015-11-26T14:49:57Z
dc.date2015-06-30T20:27:27Z
dc.date2015-11-26T14:49:57Z
dc.date.accessioned2018-03-28T22:01:02Z
dc.date.available2018-03-28T22:01:02Z
dc.identifier
dc.identifierRevista Brasileira De Medicina. , v. 68, n. 9, p. 269 - 273, 2011.
dc.identifier347264
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-80055119456&partnerID=40&md5=fdaaf7120fc9fd8a3b0ac3b0ee1871c5
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/108009
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/108009
dc.identifier2-s2.0-80055119456
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1254026
dc.descriptionThe study was performed to compare the bioavailability/bioequivalence of two Quetiapine 25 mg tablet formulations (Quetiapine from Aché Laboratórios Farmacêuticos S/A as test formulation and Seroquel® from Astrazeneca Ltda, Brazil, as reference formulation) in 48 volunteers of both sexes. The study was conducted as an open randomized two periods cross-over design with a wash out phase of one week. Plasma samples were obtained over a 36 hour interval. Plasma concentrations of Quetiapine were determined by LC-MS-MS equipment using Clozapine as internal standard. From the data obtained, the following pharmacokinetics parameters were calculated: AUC0-t′, AUC0-∞ and Cmax′ Geometric mean of Quetiapine/Seroquel® 25 mg was 99.96% for AUC 0-t′ 100.12% for AUC0-8 and 92.59% for C max′ the 90% confidence intervals were 93.58-106.77%, 93.88-106.78% and 83.22-103.01%, respectively. Since the 90% confidence intervals for Cmax′ AUC0-t and AUC 0-∞ were within the range of 80-125% proposed by Food and Drug Administration and ANVISA (the National Health Surveillance Agency of Brasil), it was concluded that Quetiapine 25 mg Tablet was bioequivalent to Seroquel® 25 mg tablet, and so the test product can be considered interchangeable in normal medical practice. © Copyright Moreira Jr. Editora. Todos os direitos reservados.
dc.description68
dc.description9
dc.description269
dc.description273
dc.descriptionAbi-Dargham, A., Laruelle, M., Aghajanian, G.K., Charney, D., Krystal, J., The role of serotonin in the pathophysiology and treatment of schizophrenia (1997) Journal of Neuropsychiatry and Clinical Neurosciences, 9 (1), pp. 1-17
dc.descriptionBarrett, B., Holcapek, M., Huclova, J., Borek-Dohalsky, V., Fejt, P., Nemec, B., Jelinek, I., Validated HPLC-MS/MS method for determination of quetiapine in human plasma (2007) Journal of Pharmaceutical and Biomedical Analysis, 44 (2), pp. 498-505. , DOI 10.1016/j.jpba.2007.03.034, PII S0731708507002051, Hyphenated Techniques in Pharmaceutical and Biomedical Analysis 2006
dc.descriptionBorkar, B.H., Vidhate, S., Lohiya, R.T., Umekar, M.J., Spectrophotometric Determination of an Atypical Antipsychotic Compound in Pharmaceutical Formulation (2009) International Journal of ChemTech Research, 1, pp. 1153-1161
dc.descriptionCalabrese, J.R., Keck Jr., P.E., Macfadden, W., Minkwitz, M., Ketter, T.A., Weisler, R.H., Cutler, A.J., Mullen, J., A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression (2005) American Journal of Psychiatry, 162 (7), pp. 1351-1360. , DOI 10.1176/appi.ajp.162.7.1351
dc.descriptionCopolov, D.L., Link, C.G.G., Kowalcyk, B., A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia (2000) Psychological Medicine, 30 (1), pp. 95-105. , DOI 10.1017/S0033291799001476
dc.descriptionDeVane, C.L., Nemeroff, C.B., Clinical Pharmacokinetics of Quetiapine: An Atypical Antipsychotic (2001) Clinical Pharmacokinet, 40, pp. 509-522
dc.descriptionFigueroa, C., Brecher, M., Hamer-Maansson, J., Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine inmediate release (2009) Prog Neuropsychopharmacol Biol Psychiatry, 33, pp. 199-204
dc.descriptionGoldstein, J.M., Atypical antipsychotic drugs: Beyond acute psychosis, new directions (1999) Emerging Drugs, 4, pp. 127-151
dc.descriptionJudd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., Leon, A.C., Keller, M.B., The long-term natural history of the weekly symptomatic status of bipolar I disorder (2002) Archives of General Psychiatry, 59 (6), pp. 530-537
dc.descriptionKapur, S., Remington, G., Serotonin-dopamine interaction and its relevance to schizophrenia (1996) American Journal of Psychiatry, 153 (4), pp. 466-476
dc.descriptionKeck, P., McIntyre, R., Shelton, R., Bipolar depression: Best practices for the outpatient (2007) CNS Spectr, 12, pp. 1-16
dc.descriptionMahatthanatrakul, W., Rattana, S., Sriwiriyajan, S., Wongnawa, M., Ridtitid, W., Bioequivalence study of a generic quetiapine in healthy male volunteers (2008) International Journal of Clinical Pharmacology and Therapeutics, 46, pp. 489-496
dc.descriptionMario, A., Michael, E., The Role of Quetiapine Extended Release in the Treatment of Bipolar Depression (2010) Adv Ther, 27, pp. 1-11
dc.descriptionPeuskens, J., A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia (1997) Acta Psychiatr Scand, 96, pp. 265-273
dc.descriptionRayan, J., Lena, D., Martha, S., Role of extended release quetiapine in the management of bipolar disorders (2010) Neuropsychiatr Dis Treat, 6, pp. 29-35
dc.descriptionThase, M.E., Macfadden, W., Weisler, R.H., Chang, W., Paulsson, B., Khan, A., Calabrese, J.R., Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study) (2006) Journal of Clinical Psychopharmacology, 26 (6), pp. 600-609. , DOI 10.1097/01.jcp.0000248603.76231.b7, PII 0000471420061200000009
dc.descriptionVieta, E., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies (2005) Current Medical Research and Opinion, 21 (6), pp. 923-934. , DOI 10.1185/030079905X46340, 2971
dc.languagept
dc.publisher
dc.relationRevista Brasileira de Medicina
dc.rightsfechado
dc.sourceScopus
dc.titleBioequivalence Study And Pharmacokinetic Evaluation Of Two Quetiapine Formulations In Healthy Volunteers After A Single Dose Administration [estudo De Bioequivalência E Avaliação Farmacocinética De Duas Formulações De Quetiapina Em Voluntários Sadios Após Administração De Dose única]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución